Chugai Pharmaceutical (OTCMKTS:CHGCY) was upgraded by equities researchers at The Goldman Sachs Group from a “neutral” rating to a “buy” rating in a report released on Thursday, The Fly reports.
CHGCY stock opened at $16.53 on Thursday. The stock has a 50-day moving average price of $16.81 and a two-hundred day moving average price of $18.09. Chugai Pharmaceutical has a 12-month low of $15.08 and a 12-month high of $28.56.
Chugai Pharmaceutical Company Profile
Read More: Pattern Day Trader
Receive News & Ratings for Chugai Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chugai Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.